Lactone stable formulation of 7-ethyl camptothecin and methods for uses thereof
US5604233A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Apr 28, 1994 |
| Grant date | Feb 18, 1997 |
| Priority date | — |
| Expiry date | Apr 28, 2014 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/1075
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
7-ethyl camptothecin (ECPT), an active metabolite of the camptothecin analog CPT-11, is poorly soluble in water. Because of its poor water solubility, ECPT has not been directly administered by parenteral or oral routes in human patients for the purpose of inhibiting the growth of cancer cells. There is also unpredictable interpatient variability in the metabolic production of ECPT from CPT-11 which limits the utility of CPT-11. This invention overcomes these limitations by teaching novel pharmaceutically acceptable lactone stable ECPT formulations for the direct administration of ECPT. The claimed invention also describes novel dosages, schedules, and routes of administration of the lactone stable ECPT formulations to patients with various forms of cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.